Copyright © 2019. Inderes Oy. All rights reserved.

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
19.3.
2021

Cantargia AB today announced new preclinical results strengthening the development plan of the antibody CAN10 for treatment of myocarditis and systemic sclerosis. In preclinical studies of myocarditis, CAN10 significantly counteracted disease development. CAN10 also potently decreased inflammatory disease in other models used to investigate the CAN10 mechanism of action. The first toxicology study, investigating single dose treatment of CAN10 up to 50 mg/kg, did not identify any safety signals.

Tiedotteet
10.3.
2021

Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC). The trial is designed to complement the ongoing clinical program and subsequently broaden the development of CAN04. The phase Ib trial is planned to be performed in up to 30 patients in France and Spain. The current estimate is to start therapy in the first patient in the end of Q2 2021.

Tiedotteet
1.3.
2021

Cantargia AB ("Cantargia") will participate at several international investor conferences during March to present the company, the drug candidates CAN04 and CAN10 and future plans. For details, see below.

Muut analyysit
26.2.
2021

Cantargia stands well equipped for a successful 2021, in our view. The Q4 report offered few surprises and the promising interim results for CANFOUR provide a good outlook for further positive data generation. The strong cash balance also puts the company in a good position when negotiating potential commercial partnership agreements. We make no estimate revisions following the report but increase our DCF-based valuation range to SEK 54-59 (48-54) per share.

Tiedotteet
25.2.
2021

Cantargia AB's ("Cantargia") full year report for 2020 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Tiedotteet
17.2.
2021

Cantargia AB will publish the company's Full Year Report for the period January - December 2020 on Thursday, February 25, 2021, at 08.30 a.m. CET.

Tiedotteet
10.2.
2021

Cantargia AB today announced that the first patient with pancreatic cancer (PDAC) has started treatment in the phase IIa extension part of the CANFOUR trial, investigating combination of CAN04 and chemotherapy. The extension part has been designed to provide additional information complementing the primary cohort of 31 patients. Nine of these patients are still being treated, providing additional information on long term efficacy and safety.

Muut analyysit
4.2.
2021

Cantargia: Edison Open House interview

Cantargia

Cantargia

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.